Prevail Therapeutics
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
430 E 29th St Ste 1520, New York City, N...Phone Number
(917) 336-9310Website
www.prevailtherapeutics.comRevenue
$16.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Prevail Therapeutics
Prevail Therapeutics is focused on advancing gene therapy to address neurodegenerative and rare diseases. The company develops innovative gene therapies aimed at targeting the genetic root causes of conditions such as Parkinson's disease and Gaucher disease. Their goal is to provide treatment options that go beyond mere symptom management for patients with limited alternatives. Prevail Therapeutics conducts clinical trials to evaluate the safety and efficacy of their therapies, seeking to improve the lives of those affected by these challenging diseases.Explore more
Prevail Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Prevail Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Prevail Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Prevail Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Prevail Therapeutics
Click to see if Prevail Therapeutics had a recent Job posting/layoffs
Check out if Prevail Therapeutics is spiking on competitors!
Earning: See what the market has to say on Prevail Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Prevail Therapeutics launches new products
Funding: Get notified immidiatlly once Prevail Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Prevail Therapeutics
Compare insights from companies similar to Prevail Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Prevail Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Prevail Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Prevail Therapeutics.
Prevail Therapeutics Tech Stack
A closer look at the technologies used by Prevail Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
A front-line source in Artificial Intelligence has indicated that the organization is in the midst of initiatives related to deep learning. Prevail Therapeutics Inc is currently evaluating Keras and Torch.
Machine Learning
Project
Collaboration/Web Apps, Application Development, Website, Machine Learning
Prevail Therapeutics News & Media
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (“Sangamo”, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Therapeutics (“Prevail”), a wholly owned subsidiary of Eli Lilly and Company, through which Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neuroloScribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases
ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Collaboration combines Scribe's CRISPR by Design™ approach with Prevail’s expertise in developing genetic medicines for neurological disordersCapsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases
THOUSAND OAKS, Calif., Jan. 4, 2023 /PRNewswire/ -- Capsida Biotherapeutics Inc. ("Capsida") today announced a multi-year strategic collaboration with Prevail Therapeutics ("Prevail"), a wholly owned subsidiary of Eli Lilly and Company ("Lilly"), to develop transformative genetic...Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement to Develop Novel AAV Capsids for CNS Disorders
ALACHUA, Fla.--(BUSINESS WIRE)--Lacerta Therapeutics, a leader in the development of adeno-associated virus (AAV) technologies for the treatment of central nervous system (CNS) diseases, today announced a new AAV capsid licensing and research collaboration agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The collaboration will focus on the discovery and development of novel AAV capsids for CNS diseases. “We are eager to initiate this exciting collaborativ
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Prevail Therapeutics
Sign Up For FreeTo access detailed company insights
Prevail Therapeutics is focused on advancing gene therapy to address neurodegenerative and rare diseases. The company develops innovative gene therapies aimed at targeting the genetic root causes of conditions such as Parkinson's disease and Gaucher disease. Their goal is to provide treatment options that go beyond mere symptom management for patie... Read More
